View Filing Data

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2016	Aug. 09, 2016
Document Information [Line Items]
Entity Registrant Name	KEMPHARM, INC
Entity Central Index Key	0001434647
Trading Symbol	kmph
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		14,646,982
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Assets
Cash and cash equivalents	$ 27,510	$ 32,318
Restricted cash	1,100
Marketable securities	55,134	19,002
Prepaid expenses and other current assets	824	2,758
Total current assets	84,568	54,078
Property and equipment, net	1,105	403
Long-term investments	18,850
Other long-term assets	111	109
Total assets	104,634	54,590
Liabilities and stockholders' equity (deficit)
Accounts payable and accrued expenses	5,356	4,906
Current portion of convertible notes	1,932	1,369
Current portion of term notes		2,041
Current portion of capital lease obligation	103	26
Total current liabilities	7,391	8,342
Convertible notes, net	90,389	7,412
Term notes, net		11,118
Derivative and warrant liability	6,043	37,839
Other long-term liabilities	478
Total liabilities	104,301	64,711
Commitments and contingencies (Note D)
Stockholders’ deficit:
Common stock, $0.0001 par value, 250,000,000 shares authorized, 14,646,982 shares issued and outstanding as of June 30, 2016 (unaudited); 14,490,954 shares issued and outstanding as of December 31, 2015	1	1
Additional paid-in capital	98,322	94,702
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of June 30, 2016 (unaudited) or December 31, 2015
Accumulated deficit	(97,990)	(104,824)
Total stockholders' equity (deficit)	333	(10,121)
Total liabilities and stockholders' equity (deficit)	$ 104,634	$ 54,590

Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	14,646,982	14,490,954
Common stock, shares outstanding (in shares)	14,646,982	14,490,954
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Unaudited Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenue
Operating expenses:
Research and development	4,988	2,768	8,222	4,887
General and administrative	4,287	3,188	8,023	4,165
Total operating expenses	9,275	5,956	16,245	9,052
Loss from operations	(9,275)	(5,956)	(16,245)	(9,052)
Other income (expense):
Loss on extinguishment of debt			(4,740)
Interest expense related to amortization of debt issuance costs and discount	(393)	(477)	(835)	(954)
Interest expense on principal	(1,475)	(654)	(2,625)	(1,286)
Fair value adjustment	20,763	(22,661)	31,041	(24,423)
Interest and other income	144	5	246	6
Total other income (expense)	19,039	(23,787)	23,087	(26,657)
Income (loss) before income taxes	9,764	(29,743)	6,842	(35,709)
Income tax benefit (expense)	4		(8)	(7)
Net income (loss)	$ 9,768	$ (29,743)	$ 6,834	$ (35,716)
Net income (loss) per share:
Basic (in dollars per share)	$ 0.59	$ (2.45)	$ 0.41	$ (4.91)
Diluted loss per share of common stock (in dollars per share)	$ (0.58)	$ (2.45)	$ (1.36)	$ (4.91)
Weighted average common shares outstanding:
Basic (in shares)	14,597,449	12,157,514	14,546,576	7,272,326
Diluted (in shares)	15,435,322	12,157,514	15,583,390	7,272,326

Unaudited Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Series D-1 Redeemable Convertible Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Series D-1 redeemable convertible preferred stock		$ 4,000
Series D Redeemable Convertible Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from exercise of warrants		2
Net income (loss)	6,834	(35,716)
Loss on extinguishment of debt	4,740
Write-off of deferred offering costs	445
Stock-based compensation expense	2,279	964
Non-cash interest expense	2,443	1,280
Amortization of debt issuance costs and debt discount	835	954
Depreciation and amortization expense	55	40
Fair value adjustment	(31,041)	24,423
Prepaid expenses and other current assets	1,934	976
Other long-term assets	(2)
Accounts payable and accrued expenses	(693)	(2,175)
Other long-term liabilities	32
Net cash used in operating activities	(12,139)	(9,254)
Purchases of property and equipment	(219)	(40)
Restricted cash for collateral	(1,100)
Purchases of marketable securities and long-term investments	(65,627)
Maturity of marketable securities	10,645
Net cash used in investing activities	(56,301)	(40)
Proceeds from issuance of debt, net of discounts and commissions	82,800
Repayment of term notes and related accrued interest	(18,621)
Proceeds from initial public offering, net of discounts and commissions		59,892
Payment of deferred offering costs		(668)
Payment of debt and stock issuance costs	(673)
Repayment of obligations under capital lease	(15)	(15)
Proceeds from exercise of warrants	141	51
Net cash provided by financing activities	63,632	63,262
Net (decrease) increase in cash and cash equivalents	(4,808)	53,968
Cash and equivalents, beginning of period	32,318	10,255
Cash and equivalents, end of period	27,510	64,223
Supplemental cash flow information:
Cash paid for interest	182
Unpaid offering costs charged to equity		1,870
Transfer of warrants to equity upon exercise	755
Fixed assets included in accounts payable and accrued expenses	50
Conversion of preferred stock into common stock upon initial public offering		28,209
Reclassification of 2013 warrants to equity		1,110
Fixed assets financed under a capital lease agreement	$ 548	$ 42

Note A - Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	A. Description of Business and Basis of Presentation Organizati on KemPharm, Inc. (the “ Company”) is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs. Through the use of its Ligand Activated Therapy (“LAT”) platform technology, the Company is able to initiate and pursue the development of improved versions of widely prescribed, approved drugs. The Company was formed on October 30, 2006, and incorporated in Iowa, and reorganized in Delaware on May 30, 2014. The Company has experienced recurring losses from operations and negative operating cash flows due to its ongoing research and development of its potential product candidates. The Company also has an accumulated deficit at June 30, 2016. Various internal and external factors will affect whether and when the candidates become approved drugs and how significant their market share will be. The length of time and cost of developing and commercializing these candidates and/or failure of them at any stage of the drug approval process will materially affect the Company’s financial condition and future operations. Based upon its current operating plan, the Company believes that its existing cash and cash equivalents, restricted cash, marketable securities and long-term investments will enable it to fund its operating expenses and capital expenditure requirements through at least the next 24 months. The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of Americ a for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and related notes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included in the accompanying financial statements. Operating results for the three and six months ended June 30, 2016, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2016. This interim information should be read in conjunction with the audited financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the Securities and Exchange Commission (“SEC”) on March 15, 2016. Reverse Stock Split On April 2, 2015, the Company effected a 1-for -7.5 reverse stock split of its issued common stock. All applicable share data, per share amounts and related information in the unaudited condensed financial statements and notes thereto have been adjusted retroactively to give effect to the 1-for-7.5 reverse stock split. Initial Public Offering In April 2015, the Company completed an initial public offering (“ IPO”) of its common stock. In connection with the initial closing of the IPO, the Company sold an aggregate of 5,090,909 shares of common stock at a price to the public of $11.00 per share. In May 2015, the underwriters in the IPO exercised their option to purchase additional shares pursuant to which the Company sold an additional 763,636 shares of common stock at a price equal to the public price of $11.00 per share. In the aggregate, net proceeds from the IPO, including net proceeds from the underwriters’ exercise of their option to purchase additional shares, were $59.9 million, after deducting underwriting discounts and commissions of $4.5 million. In addition, offering expenses totaled $2.8 million. Upon completion of the IPO, all outstanding shares of the Company’s redeemable convertible preferred stock were converted or reclassified into 5,980,564 shares of common stock and all outstanding warrants to acquire shares of the Company’s redeemable convertible preferred stock became warrants to acquire the Company’s common stock. In connection with the IPO, the Company amended and restated its Amended and Restated Certificate of Incorporation to change the authorized capital stock to 250,000,000 shares, designated as common stock, and 10,000,000 shares, designated as preferred stock, each with a par value of $0.0001 per share. Reclassifications During the first quarter of 2016 the Company adopted Accounting St andards Update (“ASU”) 2015-03, Interest – Imputation of Interest (Subtopic 835-30) (“ASU 2015-03”), which requires the debt issuance costs related to a recognized debt liability be presented in the balance sheet as direct deduction from the carrying amount of that debt liability, consistent with the presentation of debt discounts. The adoption of ASU 2015-03 reduced the Company’s assets and liabilities by the amount of the debt issuance costs, which were $4.0 million and $1.1 million at June 30, 2016 and December 31, 2015, respectively. This reclassification had no effect on reported net income (loss).

Note B - Summary of Significant Accounting Policies	6 Months Ended
Note B - Summary of Significant Accounting Policies	Jun. 30, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	B. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with accounting principles gen erally accepted in the United States of America requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. On an ongoing ba sis, the Company evaluates its estimates, including those related to the useful lives of property and equipment, and assumptions used for purposes of determining stock-based compensation, income taxes, and the fair value of the derivative and warrant liability, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Application of New or Revised Accounting Standards —Adopted From time to time, the Financial Accounting Standards Board (the “ FASB”) or other standard-setting bodies issue accounting standards that are adopted by the Company as of the specified effective date. On April 5, 2012, President Obama signed the Jump-Start Our Business Startups Act (the “ JOBS Act”) into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than public companies must adopt the standards. The Company has elected not to take advantage of the extended transition period afforded by the JOBS Act and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. In June 2014, the FASB issued ASU 2014-12, Compensation–Stock Compensation (Topic 718): Accounting for Share-Based Payments when the Terms of an Award Provide that a Performance Target Could Be Achieved After the Requisite Service Period (“ASU 2014-12”). The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Entities may apply ASU 2014-12 either (a) prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If retrospective transition is adopted, the cumulative effect of applying this ASU as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. Additionally, if retrospective transition is adopted, an entity may use hindsight in measuring and recognizing the compensation cost. The Company prospectively adopted ASU 2014-12 effective January 1, 2016. The adoption of ASU 2014-12 did not have a material impact on the financial statements as the Company does not have any performance-based awards whereby performance could be achieved after the requisite service period. In January 2015, the FASB issued ASU No. 2015-01, Income Statement - Extraordinary and Unusual Items (Subtopic 225-20); Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items (“ASU 2015-01”) , which eliminates from GAAP the concept of extraordinary items, stating that the concept causes uncertainty because (1) it is unclear when an item should be considered both unusual and infrequent and (2) users do not find the classification and presentation necessary to identify those events and transactions. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The Company adopted ASU 2015-01 effective January 1, 2016. The adoption of ASU 2015-01 did not have a material impact on the Company’s financial statements as the Company had no extraordinary and/or unusual items recorded in prior periods. In April 2015, the FASB issued ASU 2015-03, which requires the debt issuance costs related to a recognized debt liability be presented in the balance sheet as direct deduction from the carrying amount of that debt liability, consistent with the presentation of debt discounts. The adoption of ASU 2015-03 reduced the Company’s assets and liabilities by the amount of the debt issuance costs, which were $4.0 million and $1.1 million at June 30, 2016 and December 31, 2015, respectively. This reclassification had no effect on reported net income (loss). Application of New or Revised Accounting Standards—Not Yet Adopted In May 2014, the FASB issued guidance codified in ASC Topic 606, Revenue Recognition—Revenue from Contracts with Customers ("ASC 606") , which amends the guidance in former ASC 605, Revenue Recognition , and becomes effective beginning January 1, 2018. The Company is currently evaluating the impact of the provisions of ASC 606 on its financial statements and disclosures. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”), which amends ASC Subtopic 205-40 to provide guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related disclosures. Specifically, the amendments (1) provide a definition of the term “substantial doubt,” (2) require an evaluation every reporting period, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated and (6) require an assessment for a period of one year after the date that financial statements are issued. ASU 2014-15 is effective for fiscal years ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently evaluating the impact of the adoption of ASU 2014-15 on its financial statements and disclosures. In November 2015, the FASB issued ASU 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes (Topic 740) (“ASU 2015-17”), which requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This update applies to all entities that present a classified statement of financial position. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company does not expect this standard to have a material impact on its financial statements upon adoption. In January 2016, the FASB issued ASU 2016-01, Financial Instruments Overall – Recognition and Measurement of Financial Assets and Liabilities (Topic 825-10) (“ASU 2016-01”), which provides several updates related to Topic 825-10. This update applies to all entities that hold financial assets or owe financial liabilities. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company does not expect this standard to have a material impact on its financial statements upon adoption. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”), which requires lessees to recognize assets and liabilities for operating leases with lease terms greater than twelve months in the balance sheet. The update also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and disclosures. In March 2016, the FASB issued ASU 2016-06, Derivatives and Hedging (Topic 815), Contingent Put and Call Options in Debt Instruments (“ASU 2016-06”), which clarifies the requirements for assessing whether contingent call and put options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. ASU 2016-06 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-06 on its financial statements and disclosures. In March 2016, the FASB issued ASU 2016-09, Compensation–Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”), which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-09 on its financial statements and disclosures.

Note C - Debt Obligations

6 Months Ended

Jun. 30, 2016

Notes to Financial Statements

Debt Disclosure [Text Block]

Debt Obligations

Deerfield Facility Agreement

On June

2, 2014, the Company entered into a $60 million facility agreement (the “Deerfield Facility Agreement”) with Deerfield Private Design Fund III, LP (“Deerfield”). The first payment to the Company under the terms of the Deerfield Facility Agreement consisted of a term loan of $15 million (the “Term Notes”) and a senior secured loan of $10 million (the “Deerfield Convertible Notes”). As of June 30, 2016, Deerfield is no longer obligated to provide the Company any additional disbursements under the Deerfield Facility Agreement. All loans issued under the Deerfield Facility Agreement bear interest at 9.75% per annum. Deerfield may convert any portion of the outstanding principal and any accrued but unpaid interest on the Deerfield Convertible Notes into shares of the Company’s common stock at an initial conversion price of $5.85 per share.

The Company also issued to Deerfield a warrant to purchase 14,423,

076 shares of Series D redeemable convertible preferred stock (“Series D Preferred”) at an exercise price of $0.78 per share, which is exercisable until June 2, 2024 (the “Deerfield Warrant”). Upon completion of the IPO, the Deerfield Warrant automatically converted into a warrant to purchase 1,923,077 shares of the Company’s common stock at an exercise price of $5.85 per share. This warrant qualifies as a participating security under ASC Topic 260,

Earnings per Share

and is treated as such in the earnings per share calculation (Note I). In the event that a Major Transaction occurs, as defined below, Deerfield may require the Company to redeem the Deerfield Warrant for a cash amount equal to the Black-Scholes value of the portion of the Deerfield Warrant to be redeemed (the “Put Option”). A Major Transaction is (i) a consolidation, merger, exchange of shares, recapitalization, reorganization, business combination or other similar event; (ii) the sale or transfer in one transaction or a series of related transactions of all or substantially all of the assets of the Company; (iii) a third-party purchase, tender or exchange offer made to the holders of outstanding shares, such that following such purchase, tender or exchange offer a change of control has occurred; (iv) the liquidation, bankruptcy, insolvency, dissolution or winding-up affecting the Company; (v) the shares of the Company’s common stock cease to be listed on any eligible market; and (vi) at any time, the shares of the Company’s common stock cease to be registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

In addition, the Company issued to Deerfield 1,923,077

shares of Series D Preferred as consideration for the loans provided to the Company under the Deerfield Facility Agreement. Upon completion of the IPO, these shares automatically reclassified into 256,410 shares of the Company’s common stock. The Company recorded the fair value of the shares of Series D Preferred of $1.5 million, to debt issuance costs on the date of issuance. The Company recorded the fair value of the Deerfield Warrant and the embedded Put Option to debt discount on the date of issuance. The debt issuance costs and debt discount are amortized over the term of the related debt and the expense is recorded as interest expense in the statements of operations.

The Company must repay one-third of the outstanding principal amount of all debt i

ssued under the Deerfield Facility Agreement on the fourth and fifth anniversaries of the Deerfield Facility Agreement. The Company is then obligated to repay the balance of the outstanding principal amount on February 14, 2020. The Company prepaid all outstanding interest and principal on the Term Notes in February 2016.

Interest accrued on outs

tanding debt under the Deerfield Facility Agreement is due quarterly in arrears. Upon notice to Deerfield, the Company may choose to have one or more of the first eight of such scheduled interest payments added to the outstanding principal amount of the debt issued under the Deerfield Facility Agreement, provided that all such interest was due on July 1, 2016. The Company elected this option on all eight of the scheduled interest payments through June 30, 2016. The accrued interest added to outstanding principal is reflected in the condensed balance sheets as current portion of convertible notes and was paid to Deerfield on July 1, 2016.

Second Amendment to Senior Secured Co

nvertible Note and Warrant

On January 6, 2016, the Company entered into a Second Amendment (the “

Second Amendment”) to the Deerfield Convertible Notes and Deerfield Warrant, by and between the Company and Deerfield. The Second Amendment, among other things, clarified the calculation of an anti-dilution adjustment of the conversion price and exercise price of the Deerfield Convertible Notes and Deerfield Warrant, respectively, in the event that the Company effects a firm commitment underwritten public offering of its securities. Except as modified by the Second Amendment and Third Amendment (as described below), all terms and conditions of the Deerfield Convertible Notes and Deerfield Warrant remain in full force and effect.

Issuance of 2021 Notes and Thi

rd Amendment to Senior Secured Convertible Note and Warrant

On February 9, 2016, the Company issued $86.25 million aggregate principal amount of its 5.50% Senior Convertible Notes due 2021 (the “

2021 Notes”) to Cowen and Company, LLC and RBC Capital Markets, LLC., as representatives of the several initial purchasers (the “Initial Purchasers”), who subsequently resold the 2021 Notes to qualified institutional buyers (the “Note Offering”) in reliance on the exemption from registration provided by Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

The net proceeds from the Note Offering were approximately $82.8 million, after deducting the Initial Purchasers

’ discount and estimated offering expenses. Concurrent with the Note Offering, the Company used approximately $18.6 million of the net proceeds from the Note Offering to repay in full the Term Notes, plus all accrued but unpaid interest, a make whole interest payment and a prepayment premium on the Term Notes.

The 2021

Notes were issued pursuant to an Indenture, dated as of February 9, 2016 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. Interest on the 2021 Notes will be payable semi-annually in cash in arrears on February 1 and August 1 of each year, beginning on August 1, 2016, at a rate of 5.50% per year. The 2021 Notes mature on February 1, 2021 unless earlier converted or repurchased. The 2021 Notes are not redeemable prior to the maturity date, and no sinking fund is provided for the 2021 Notes.

The 2021 Notes are convertible at an initial conversion rate of 58.4454 shares of the Company

’s common stock per $1,000 principal amount of the 2021 Notes, subject to adjustment under the Indenture, which is equal to an initial conversion price of approximately $17.11 per share of common stock. Upon conversion, the 2021 Notes will be settled in shares of the Company’s common stock, together with a cash payment in lieu of delivering any fractional share. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its 2021 Notes in connection with such a corporate event in certain circumstances

If the Company undergoes a “

fundamental change” (as defined in the Indenture), holders may require that the Company repurchase for cash all or any portion of their 2021 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2021 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, holders who convert their 2021 Notes on or after the date that is one year after the last date of original issuance of the 2021 Notes may also be entitled to receive, under certain circumstances, an interest make-whole payment payable in shares of the Company’s common stock. The Company is bifurcating the fundamental change and make-whole interest payment provisions as embedded derivatives and marking them to fair value each reporting period (Note H).

The Indenture includes customary terms and covenants, including certain events

of default after which the 2021 Notes may be due and payable immediately.

In connection with the Note Offering, on February 3, 2016, the Company entered into a Third Amendment (the “

Third Amendment”) to the Deerfield Facility Agreement, Deerfield Convertible Notes and Deerfield Warrant with Deerfield. The Third Amendment, among other things, eliminated the Company’s ability to require Deerfield to convert the Deerfield Convertible Notes into Company common stock. In addition, pursuant to the Third Amendment, Deerfield consented to the prepayment of the Term Notes and the issuance of the 2021 Notes. Except as modified by the Third Amendment, all terms and conditions of the Deerfield Facility Agreement remain in full force and effect.

Line of Credit

e Company has a $100,000 credit agreement with Wells Fargo Bank, N.A. (the “Second Line of Credit Agreement”). As of June 30, 2016, the Company had $73,000 available under the Second Line of Credit Agreement.

The draws from this line of credit line are recorded in accounts payable and accrued expenses in the balance sheet. The Second Line of Credit Agreement is uncollateralized and contains no financial covenants. Borrowings under the Second Line of Credit Agreement carry interest at a rate equal to the prime rate plus 9.99% per annum. The Company is required to make interest only payments on any draws under the Second Line of Credit Agreement. The draws from this line of credit do not begin accumulating interest until the draw has been outstanding at least thirty days. The interest rate under the Second Line of Credit Agreement was 13.49% as of June 30, 2016.

During the second quarter of 2016, the Company closed its prior $50,000 credit agreement with Wells Fargo Bank, N.A.

Also during the second quarter of 2016, the Company opened a new line of credit with a total borrowing capacity of $1.1 million with City National Bank of Florida (the "Third Line of Credit Agreement") to support several irrevocable letters of credit issued by the bank on behalf of the Company. The line of credit has a maturity date of January 31, 2018. As of June 30, 2016, the Company had no outstanding balance under the line of credit. The Third Line of Credit Agreement is collateralized by a restricted money market account, equal to the total amount of the borrowing capacity under the line of credit, held by the same bank institution. The money market account is reported as restricted cash on the balance sheet. The line of credit contains no financial covenants.

Borrowings under the Third Line of Credit Agreement carry interest at a rate equal to the prime rate plus 2.00% per annum.

The interest rate under the Third Line of Credit Agreement was 2.47% as of June 30, 2016.

Note D - Commitments and Contingencies	6 Months Ended
Note D - Commitments and Contingencies	Jun. 30, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	D. Commitments and Contingencies From time to time, the Company is involved in various legal proceedings arising in the normal course of business. For some matters, a liability is not probable or the amount cannot be reasonably estimated and, therefore, an accrual h as not been made. However, for such matters when it is probable that the Company has incurred a liability and can reasonably estimate the amount, the Company accrues and discloses such estimates.

Note E - Preferred Stock and Warrants	6 Months Ended
Note E - Preferred Stock and Warrants	Jun. 30, 2016
Notes to Financial Statements
Preferred Stock [Text Block]	E. Preferred Stock and Warrants Authorized, Issued, and Outstanding Preferred Stock In April 2015, the Company amended and restated its Certificate of Incorporation to decrease the number of its authorized shares of preferred stock to 10,000,000 shares with a par value of $0.0001 per share. As described in Note A, in April 2015, the Comp any completed an IPO of its common stock. Upon completion of the IPO, all outstanding shares of the Company’s redeemable convertible preferred stock were automatically converted or reclassified into an aggregate of 5,980,564 shares of the Company’s common stock. As of June 30, 2016, the Company had 10,000,000 shares of authorized and undesignated preferred stock and did not have any preferred stock outstanding. Series D-1 Redeemable Convertible Preferred Stock In February 2015, the Company entered int o a stock purchase agreement with Cowen KP Investment, LLC in which Cowen KP Investment, LLC agreed to purchase and the Company agreed to sell 3,200,000 shares of the Company’s Series D-1 redeemable convertible preferred stock (“Series D-1 Preferred”) for $1.25 per share, or an aggregate of $4 million. Upon completion of the IPO, these shares automatically converted into 415,584 shares of the Company’s common stock. Warrants As described in Note A, in April 2015, the Company completed an IPO of its common stock. Upon completion of the IPO, and as of June 30, 2016, warrants to purchase 15,499,324 shares of Series D Preferred were reclassified into warrants to purchase 2,066,543 shares of the Company’s common stock. During 2013, the Company issued $3.8 million of convertible notes and the warrants (the “ 2013 Warrants”) to purchase 1,079,453 shares of equity securities in a future financing meeting specified criteria (a “Qualified Financing”). The 2013 Warrants allow the holders to purchase shares of the same class and series of equity securities issued in the Qualified Financing for an exercise price equal to the per share price paid by the purchasers of such equity securities in the Qualified Financing. When the Company entered into the Deerfield Facility Agreement, the 2013 Warrants became warrants to purchase 1,079,453 shares of Series D Preferred. Upon completion of the IPO, the 2013 Warrants automatically converted into warrants to purchase 143,466 shares of the Company’s common stock at an exercise price of $5.85 per share. The 2013 Warrants, if unexercised, expire on the earlier of June 2, 2019, or upon a liquidation event. On June 2, 2014, pursuant to the terms of the Deerfield Facility Agreement, the Company issued the Deerfield Warrant to purchase 14,423,076 shares of Series D Preferred. The Company recorded the fair value of the Deerfield Warrant as a debt discount and a warrant liability. The Deerfield Warrant, if unexercised, expires on the earlier of June 2, 2024, or upon a liquidation event. Upon completion of the IPO, the Deerfield Warrant automatically converted into a warrant to purchase 1,923,077 shares of the Company’s common stock at an exercise price of $5.85 per share. The Company is amortizing the debt discount to interest expense over the term of the Deerfield Convertible Notes. The Company determined that the 2013 Warrants and Deerfield Warrant should be recorded as a liability and stated at fair value a t each reporting period upon inception. As stated above, upon completion of the IPO, the 2013 Warrants and the Deerfield Warrant automatically converted into warrants to purchase the Company’s common stock. The Company determined that the 2013 Warrants should be marked to fair value and reclassified to equity upon closing of the IPO. The Deerfield Warrant remains classified as a liability and is recorded at fair value at each reporting period since it can be settled in cash. Changes to the fair value of the warrant liability are recorded through the statements of operations as a fair value adjustment (Note H).

Note F - Common Stock and Warrants

6 Months Ended

Jun. 30, 2016

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

Common Stock and Warrants

Authorized, Issued, and Outstanding Common Shares

In April 2015, the Company amended and restated its Certificate

of Incorporation to increase the number of its authorized shares of common stock to 250,000,000 shares. Of the authorized shares, 14,646,982 and 14,490,954 shares of common stock were issued and outstanding at June 30, 2016 and December 31, 2015, respectively.

June 30, 2016 and December 31, 2015, the Company had reserved authorized shares of common stock for future issuance as follows:

	June 30 , 2016		December 31, 2015
Conversion of Deerfield Convertible Notes		2,088,931		1,991,219
Conversion of 2021 Notes		5,040,914		—
Outstanding awards under equity incentive plans		2,238,153		1,397,511
Outstanding common stock warrants		2,087,477		2,325,383
Possible future issuances under equity incentive plans		1,130,111		1,410,848
Total common shares reserved for future issuance		12,585,586		7,124,961

Common Stock Activity

The following table summarizes common stock activity for the

six months ended June 30, 2016:

	Shares of Common Stock
Balance at December 31, 2015		14,490,954
Common stock warrants exercised		141,095
Common stock options exercised		14,933
Balance at June 30, 2016		14,646,982

The Company calculates the fair value of common stock warrants using a Monte Carlo simulation. There were warrants exercised for an aggregate of 141,095

and 12,251 shares of common stock during the six months ended June 30, 2016 and 2015, respectively. From 2008 through 2012, the Company issued warrants to purchase 595,920 shares of common stock in its private placement offerings of Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock (the “Underwriter Warrants”) and for leasing laboratory space. The Company accounted for the Underwriter Warrants as a derivative liability, which is adjusted to fair value at each reporting period, with the change in fair value recorded within other expenses in the statements of operations.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Note G - Stock-based Compensation

6 Months Ended

Jun. 30, 2016

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Stock-Based Compensation

The Company maintains a stock-based compensation plan (the “

Incentive Stock Plan”) that governs stock awards made to employees and directors prior to completion of the IPO.

In November 2014, the Board, and in April 2015, the Company

’s stockholders, approved the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), which became effective in April 2015. The 2014 Plan provides for the grant of stock options, other forms of equity compensation, and performance cash awards. The maximum number of shares of common stock that may be issued under the 2014 Plan is 2,846,304 as of June 30, 2016. The number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year, beginning on January 1, 2016 and ending on and including January 1, 2024, by 4% of the total number of shares of the Company’s capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Board. Pursuant to the terms of the 2014 Plan, on January 1, 2016, the common stock reserved for issuance under the 2014 Plan automatically increased by 579,638 shares.

During the three and

six months ended June 30, 2016, stock options were exercised for a total of 14,933 shares of common stock. No stock options were exercised during the three and six months ended June 30, 2015.

Stock-based compensation expense recorded under the Incentive Stock Plan and the 2014 Plan is included in the

following line items in the accompanying statements of operations (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Research and development	$	268	$	185	$	455	$	220
General and administrative		989		688		1,824		744
	$	1,257	$	873	$	2,279	$	964

There was no stock-based compensation expense related to performance-based incentive awards recognized during the three months ended June 30, 2016. During the

six months ended June 30, 2016, the Company recognized $29,000 of stock-based compensation expense related to performance-based incentive awards included in research and development expenses in connection with the vesting of stock options exercisable for an aggregate of 13,333 shares of common stock as a result of the acceptance of the new drug application for Apadaz for priority review in February 2016. During the three and six months ended June 30, 2015, the Company recognized approximately $0.6 million and $0.7 million, respectively, of stock-based compensation expense related to performance-based incentive awards included in general and administrative expenses and $0.2 million of stock-based compensation expense related to performance-based incentive awards included in research and development expenses. These awards were in connection with the grant of fully vested stock options exercisable for an aggregate of 134,665 shares of common stock during the first quarter of 2015 and upon completion of the Company's IPO during the second quarter of 2015.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Note H - Fair Value of Financial Instruments

6 Months Ended

Jun. 30, 2016

Notes to Financial Statements

Fair Value Disclosures [Text Block]

Fair Value of Financial Instruments

The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash and accounts payable

, approximate their respective fair values due to the short-term nature of such instruments.

The fair value of the Deerfield Convertible Notes and the 2021 Notes was $8.5 million and

$48.0 million, respectively, at June 30, 2016. Both the Deerfield Convertible Notes and the 2021 Notes fall within Level 3 of the fair value hierarchy as their value is based on the credit worthiness of the Company, which is an unobservable input.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgements t

o be made. The following table summarizes the conclusions reached regarding fair value measurements as of June 30, 2016, and December 31, 2015 (in thousands):

	Balance at June 30 , 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Underwri ter Warrant liability	$	53	$	—	$	—	$	53
Deerfield Warrant liability		5,404		—		—		5,404
Embedded Put Option		557		—		—		557
Fundamental change and make-whole interest provisions embedded in 2021 Notes		29		—		—		29
Total liabilities	$	6,043	$	—	$	—	$	6,043
Trading securities:
Certificates of deposit		11,911		11,911		—		—
Government bonds		62,073		62,073		—		—
Total assets	$	73,984	$	73,984	$	—	$	—

	Balance at December 31, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Underwriter Warrant liability	$	3,877	$	—	$	—	$	3,877
Deerfield Warrant liability		33,750		—		—		33,750
Embedded Put Option		212		—		—		212
Total liabilities	$	37,839	$	—	$	—	$	37,839
Trading securities:
Certificates of deposit		8,951		8,951		—		—
Government bonds		10,051		10,051		—		—
Total assets	$	19,002	$	19,002	$	—	$	—

The Company

’s Underwriter Warrant liability, Deerfield Warrant liability, embedded Put Option, and the fundamental change and the make-whole interest provisions embedded in the 2021 Notes, as well as the trading securities are measured at fair value on a recurring basis. As of June 30, 2016 and December 31, 2015, the Underwriter Warrant liability, Deerfield Warrant liability, and embedded Put Option are reported on the balance sheet in derivative and warrant liability, while the trading securities are reported on the balance sheet in marketable securities and long-term investments. The 2021 Notes were issued during the first quarter of 2016 and the fundamental change and make-whole interest provisions embedded in the 2021 Notes are reported on the balance sheet in derivative and warrant liability. The Company used a Monte Carlo simulation to value the Underwriter Warrant liability and the embedded Put Option at June 30, 2016 and December 31, 2015. A Monte Carlo simulation was also used to value the fundamental change and make-whole interest provisions embedded in the 2021 Notes as of the issuance date and June 30, 2016. Significant unobservable inputs used in measuring the fair value of these financial instruments included the Company’s estimated enterprise value, an estimate of the timing of a liquidity or fundamental change event, a present value discount rate and an estimate of the Company’s stock volatility using the volatilities of guideline peer companies. Changes in the fair value of the Underwriter Warrant liability, the Deerfield Warrant liability, the embedded Put Option and the fundamental change and make-whole interest provisions embedded in the 2021 Notes are reflected in the statements of operations as a fair value adjustment. A 10% increase in the enterprise value would result in an increase of $11,000 in the estimated fair value of the Underwriter Warrant liability, an increase of $0.6 million in the estimated fair value of the Deerfield Warrant liability, an increase of $38,000 in the estimated fair value of the embedded Put Option, and an increase of $7,000 in the estimated fair value of the fundamental change and make-whole interest provisions embedded in the 2021 Notes at June 30, 2016.

A reconciliation of the beginning and ending balances for the deriv

ative and warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
Balance at beginning of period	$	27,479		$	17,728		$	37,839		$	15,966
Reclassification of 2013 Convertible Notes		—			(1,110	)		—			(1,110	)
Exercise of warrants		(673	)		—			(755	)		—
Adjustment to fair value		(20,763	)		22,661			(31,041	)		24,423
Balance at end of period	$	6,043		$	39,279		$	6,043		$	39,279

From June 2013 through October 2013, the Company issued 10.0% unsecured convertible promissory notes (the “2013 Convertible Notes”). The 2013 Convertible Notes accrued interest from the date of issuance through the maturity date, with such interest payable in cash upon maturity.

The 2013 Convertible Notes did not have a stated maturity date and instead matured under various scenarios, such as the sale of substantially all of the assets of the Company, dissolution of the Company, failure to observe covenants, and voluntary or involuntary bankruptcy. In accordance with the terms of the 2013 Convertible Notes, and effected by the written consent of the holders of a majority of the outstanding principal of such notes, on June 2, 2014, the principal amount of the 2013 Convertible Notes and all accrued interest converted into shares of Series D Preferred. Upon the conversion of the 2013 Convertible Notes, the embedded conversion feature of the 2013 Convertible Notes and Put Option were marked to fair value and recorded in derivative and warrant liability. Upon the IPO, in April 2015, the Company reclassified the 2013 Convertible Notes into equity.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note I - Net Income (Loss) Per Share

6 Months Ended

Jun. 30, 2016

Notes to Financial Statements

Earnings Per Share [Text Block]

Net Income (Loss) Per Share

Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by th

e weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current year earnings that participating securities would have been entitled to receive pursuant to their dividend rights had all of the year’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss as the holders of the participating securities have no obligation to fund losses. Diluted net loss per common share is computed under the two-class method by using the weighted average number of shares of common stock outstanding plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options and warrants. In addition, the Company analyzes the potential dilutive effect of the outstanding participating securities under the if-converted method when calculating diluted earnings per share in which it is assumed that the outstanding participating securities convert or are reclassified into common stock at the beginning of the period. The Company reports the more dilutive of the approaches (two-class or if-converted) as its diluted net income per share during the period. Due to the existence of net losses for the three and six month periods ended June 30, 2015, basic and diluted loss per share were the same, as the effect of potentially dilutive securities would have been anti-dilutive.

The following securities, presented on a com

mon stock equivalent basis, have been excluded from the calculation of weighted-average shares of common stock outstanding for the three and six month periods ended June 30, 2016 and 2015 because their effect is anti-dilutive:

	Three and Six Months Ended June 30,
	2016		2015
Warrants to purchase common stock		164,400		2,650,212
Awards under equity incentive plans		2,238,153		943,304
Deerfield Convertible Notes		2,088,931		1,896,843
2021 Notes		5,040,914		—
Total		9,532,398		5,490,359

The following table reconciles basic earnings per share of common stock to diluted earnings per share of common stock for the three and six months ended June 30, 2016 (in thousands, except per share data)

	Three Months Ended			Six Months Ended
	June 30, 2016
Basic earnings per share of common stock:
Net earnings	$	9,768		$	6,834
Less: Net earnings allocable to participating securities		(1,137	)		(798	)
Net earnings allocable to shares of common stock		8,631			6,036
Less: Dividends declared or accumulated		—			—
Undistributed earnings allocable to shares of common stock, basic	$	8,631		$	6,036
Weighted-average shares of common stock outstanding		14,597			14,547
Basic earnings per share of common stock	$	0.59		$	0.41
Diluted loss per share of common stock:
Net earnings	$	9,768		$	6,834
Less: Fair value adjustment for Deerfield stock warrants		(18,769	)		(28,001	)
Net loss allocable to shares of common stock, diluted	$	(9,001	)	$	(21,167	)
Weighted-average shares of common stock outstanding		14,597			14,547
Dilutive effect of Deerfield stock warrants		838			1,037
Weighted-average shares of common stock outstanding, diluted		15,435			15,583
Diluted loss per share of common stock	$	(0.58	)	$	(1.36	)

Significant Accounting Policies (Policies)	6 Months Ended
Significant Accounting Policies (Policies)	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Organizati on KemPharm, Inc. (the “ Company”) is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs. Through the use of its Ligand Activated Therapy (“LAT”) platform technology, the Company is able to initiate and pursue the development of improved versions of widely prescribed, approved drugs. The Company was formed on October 30, 2006, and incorporated in Iowa, and reorganized in Delaware on May 30, 2014. The Company has experienced recurring losses from operations and negative operating cash flows due to its ongoing research and development of its potential product candidates. The Company also has an accumulated deficit at June 30, 2016. Various internal and external factors will affect whether and when the candidates become approved drugs and how significant their market share will be. The length of time and cost of developing and commercializing these candidates and/or failure of them at any stage of the drug approval process will materially affect the Company’s financial condition and future operations. Based upon its current operating plan, the Company believes that its existing cash and cash equivalents, restricted cash, marketable securities and long-term investments will enable it to fund its operating expenses and capital expenditure requirements through at least the next 18 months. The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of Americ a for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and related notes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included in the accompanying financial statements. Operating results for the three and six months ended June 30, 2016, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2016. This interim information should be read in conjunction with the audited financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the Securities and Exchange Commission (“SEC”) on March 15, 2016.
Stockholders' Equity, Policy [Policy Text Block]	Reverse Stock Split On April 2, 2015, the Company effected a 1-for -7.5 reverse stock split of its issued common stock. All applicable share data, per share amounts and related information in the unaudited condensed financial statements and notes thereto have been adjusted retroactively to give effect to the 1-for-7.5 reverse stock split. Initial Public Offering In April 2015, the Company completed an initial public offering (“ IPO”) of its common stock. In connection with the initial closing of the IPO, the Company sold an aggregate of 5,090,909 shares of common stock at a price to the public of $11.00 per share. In May 2015, the underwriters in the IPO exercised their option to purchase additional shares pursuant to which the Company sold an additional 763,636 shares of common stock at a price equal to the public price of $11.00 per share. In the aggregate, net proceeds from the IPO, including net proceeds from the underwriters’ exercise of their option to purchase additional shares, were $59.9 million, after deducting underwriting discounts and commissions of $4.5 million. In addition, offering expenses totaled $2.8 million. Upon completion of the IPO, all outstanding shares of the Company’s redeemable convertible preferred stock were converted or reclassified into 5,980,564 shares of common stock and all outstanding warrants to acquire shares of the Company’s redeemable convertible preferred stock became warrants to acquire the Company’s common stock. In connection with the IPO, the Company amended and restated its Amended and Restated Certificate of Incorporation to change the authorized capital stock to 250,000,000 shares, designated as common stock, and 10,000,000 shares, designated as preferred stock, each with a par value of $0.0001 per share.
Reclassification, Policy [Policy Text Block]	Reclassifications During the first quarter of 2016 the Company adopted Accounting St andards Update (“ASU”) 2015-03, Interest – Imputation of Interest (Subtopic 835-30) (“ASU 2015-03”), which requires the debt issuance costs related to a recognized debt liability be presented in the balance sheet as direct deduction from the carrying amount of that debt liability, consistent with the presentation of debt discounts. The adoption of ASU 2015-03 reduced the Company’s assets and liabilities by the amount of the debt issuance costs, which were $4.0 million and $1.1 million at June 30, 2016 and December 31, 2015, respectively. This reclassification had no effect on reported net income (loss).
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles gen erally accepted in the United States of America requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. On an ongoing ba sis, the Company evaluates its estimates, including those related to the useful lives of property and equipment, and assumptions used for purposes of determining stock-based compensation, income taxes, and the fair value of the derivative and warrant liability, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.
New Accounting Pronouncements, Policy [Policy Text Block]	Application of New or Revised Accounting Standards—Not Yet Adopted In May 2014, the FASB issued guidance codified in ASC Topic 606, Revenue Recognition—Revenue from Contracts with Customers ("ASC 606") , which amends the guidance in former ASC 605, Revenue Recognition , and becomes effective beginning January 1, 2018. The Company is currently evaluating the impact of the provisions of ASC 606 on its financial statements and disclosures. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”), which amends ASC Subtopic 205-40 to provide guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related disclosures. Specifically, the amendments (1) provide a definition of the term “substantial doubt,” (2) require an evaluation every reporting period, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated and (6) require an assessment for a period of one year after the date that financial statements are issued. ASU 2014-15 is effective for fiscal years ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently evaluating the impact of the adoption of ASU 2014-15 on its financial statements and disclosures. In November 2015, the FASB issued ASU 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes (Topic 740) (“ASU 2015-17”), which requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This update applies to all entities that present a classified statement of financial position. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company does not expect this standard to have a material impact on its financial statements upon adoption. In January 2016, the FASB issued ASU 2016-01, Financial Instruments Overall – Recognition and Measurement of Financial Assets and Liabilities (Topic 825-10) (“ASU 2016-01”), which provides several updates related to Topic 825-10. This update applies to all entities that hold financial assets or owe financial liabilities. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company does not expect this standard to have a material impact on its financial statements upon adoption. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”), which requires lessees to recognize assets and liabilities for operating leases with lease terms greater than twelve months in the balance sheet. The update also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and disclosures. In March 2016, the FASB issued ASU 2016-06, Derivatives and Hedging (Topic 815), Contingent Put and Call Options in Debt Instruments (“ASU 2016-06”), which clarifies the requirements for assessing whether contingent call and put options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. ASU 2016-06 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-06 on its financial statements and disclosures. In March 2016, the FASB issued ASU 2016-09, Compensation–Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”), which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-09 on its financial statements and disclosures.

Note F - Common Stock and Warrants (Tables)

6 Months Ended

Jun. 30, 2016

Notes Tables

Schedule of Authorized Shares of Common Stock Reserved for Future Issuance [Table Text Block]

	June 30 , 2016		December 31, 2015
Conversion of Deerfield Convertible Notes		2,088,931		1,991,219
Conversion of 2021 Notes		5,040,914		—
Outstanding awards under equity incentive plans		2,238,153		1,397,511
Outstanding common stock warrants		2,087,477		2,325,383
Possible future issuances under equity incentive plans		1,130,111		1,410,848
Total common shares reserved for future issuance		12,585,586		7,124,961

Schedule of Common Stock Outstanding Roll Forward [Table Text Block]

	Shares of Common Stock
Balance at December 31, 2015		14,490,954
Common stock warrants exercised		141,095
Common stock options exercised		14,933
Balance at June 30, 2016		14,646,982

Note G - Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2016

Notes Tables

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Research and development	$	268	$	185	$	455	$	220
General and administrative		989		688		1,824		744
	$	1,257	$	873	$	2,279	$	964

Note H - Fair Value of Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2016

Notes Tables

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Balance at June 30 , 2016		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Underwri ter Warrant liability	$	53	$	—	$	—	$	53
Deerfield Warrant liability		5,404		—		—		5,404
Embedded Put Option		557		—		—		557
Fundamental change and make-whole interest provisions embedded in 2021 Notes		29		—		—		29
Total liabilities	$	6,043	$	—	$	—	$	6,043
Trading securities:
Certificates of deposit		11,911		11,911		—		—
Government bonds		62,073		62,073		—		—
Total assets	$	73,984	$	73,984	$	—	$	—

	Balance at December 31, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Underwriter Warrant liability	$	3,877	$	—	$	—	$	3,877
Deerfield Warrant liability		33,750		—		—		33,750
Embedded Put Option		212		—		—		212
Total liabilities	$	37,839	$	—	$	—	$	37,839
Trading securities:
Certificates of deposit		8,951		8,951		—		—
Government bonds		10,051		10,051		—		—
Total assets	$	19,002	$	19,002	$	—	$	—

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
Balance at beginning of period	$	27,479		$	17,728		$	37,839		$	15,966
Reclassification of 2013 Convertible Notes		—			(1,110	)		—			(1,110	)
Exercise of warrants		(673	)		—			(755	)		—
Adjustment to fair value		(20,763	)		22,661			(31,041	)		24,423
Balance at end of period	$	6,043		$	39,279		$	6,043		$	39,279

Note I - Net Income (Loss) Per Share (Tables)

6 Months Ended

Jun. 30, 2016

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three and Six Months Ended June 30,
	2016		2015
Warrants to purchase common stock		164,400		2,650,212
Awards under equity incentive plans		2,238,153		943,304
Deerfield Convertible Notes		2,088,931		1,896,843
2021 Notes		5,040,914		—
Total		9,532,398		5,490,359

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended			Six Months Ended
	June 30, 2016
Basic earnings per share of common stock:
Net earnings	$	9,768		$	6,834
Less: Net earnings allocable to participating securities		(1,137	)		(798	)
Net earnings allocable to shares of common stock		8,631			6,036
Less: Dividends declared or accumulated		—			—
Undistributed earnings allocable to shares of common stock, basic	$	8,631		$	6,036
Weighted-average shares of common stock outstanding		14,597			14,547
Basic earnings per share of common stock	$	0.59		$	0.41
Diluted loss per share of common stock:
Net earnings	$	9,768		$	6,834
Less: Fair value adjustment for Deerfield stock warrants		(18,769	)		(28,001	)
Net loss allocable to shares of common stock, diluted	$	(9,001	)	$	(21,167	)
Weighted-average shares of common stock outstanding		14,597			14,547
Dilutive effect of Deerfield stock warrants		838			1,037
Weighted-average shares of common stock outstanding, diluted		15,435			15,583
Diluted loss per share of common stock	$	(0.58	)	$	(1.36	)

Note A - Description of Business and Basis of Presentation (Details Textual)		1 Months Ended		6 Months Ended
	Apr. 02, 2015	May 31, 2015 USD ($) $ / shares shares	Apr. 30, 2015 $ / shares shares	Jun. 30, 2016 USD ($) $ / shares shares	Jun. 30, 2015 USD ($)	Dec. 31, 2015 USD ($) $ / shares shares
IPO [Member]
Stock Issued During Period, Shares, New Issues \| shares			5,090,909
Shares Issued, Price Per Share \| $ / shares		$ 11	$ 11
Additional Common Stock Issued During Period		$ 763,636
Proceeds from Issuance Initial Public Offering		59,900,000
Underwriting Discounts and Commissions		4,500,000
Offering Expenses		$ 2,800,000
Stock Issued During Period, Shares, Conversion of Convertible Securities \| shares		5,980,564
Preferred Stock, Par or Stated Value Per Share \| $ / shares		$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001
Stockholders' Equity Note, Stock Split, Conversion Ratio	7.5
Proceeds from Issuance Initial Public Offering					$ 59,892,000
Common Stock, Shares Authorized \| shares		250,000,000	250,000,000	250,000,000		250,000,000
Preferred Stock, Shares Authorized \| shares		10,000,000	10,000,000	10,000,000		10,000,000
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.0001		$ 0.0001		$ 0.0001
Unamortized Debt Issuance Expense				$ 4,000,000		$ 1,100,000

Note B - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Unamortized Debt Issuance Expense	$ 4,000,000	$ 1,100,000

Note C - Debt Obligations (Details Textual) - USD ($)				6 Months Ended
Note C - Debt Obligations (Details Textual) - USD ($)	Jun. 30, 2016	Feb. 09, 2016	Jun. 02, 2014	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2013
Deerfield Facility Agreement [Member] \| Term Notes [Member]
Proceeds from Secured Notes Payable			$ 15,000,000
Deerfield Facility Agreement [Member] \| Deerfield Convertible Notes [Member]
Proceeds from Secured Notes Payable			$ 10,000,000
Debt Instrument, Convertible, Conversion Price			$ 5.85
Deerfield Facility Agreement [Member] \| Series D Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			14,423,076
Own-share Lending Arrangement, Shares, Issued			1,923,077
Mandatorily Redeemable Preferred Stock, Fair Value Disclosure			$ 1,500,000
Deerfield Facility Agreement [Member] \| Deerfield Warrant [Member] \| IPO [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,923,077
Deerfield Facility Agreement [Member] \| Deerfield Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.78
Deerfield Facility Agreement [Member] \| IPO [Member]
Reclassification of Common Stock Shares			256,410
Deerfield Facility Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 60,000,000
Line of Credit Facility, Interest Rate at Period End			9.75%
Second Line of Credit Agreement [Member] \| Wells Fargo Bank, N.A. [Member] \| Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate				9.99%
Second Line of Credit Agreement [Member] \| Wells Fargo Bank, N.A. [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 100,000			$ 100,000
Debt Instrument, Interest Rate, Stated Percentage	13.49%			13.49%
Line of Credit Facility, Remaining Borrowing Capacity	$ 73,000			$ 73,000
First Line of Credit Agreement [Member] \| Wells Fargo Bank, N.A. [Member]
Line of Credit Facility, Maximum Borrowing Capacity					$ 50,000
Third Line of Credit Agreement [Member] \| City National Bank of Florida [Member] \| Prime Rate [Member]
Debt Instrument, Interest Rate, Stated Percentage	2.47%			2.47%
Debt Instrument, Basis Spread on Variable Rate	2.00%
Third Line of Credit Agreement [Member] \| City National Bank of Florida [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,100,000			$ 1,100,000
Long-term Line of Credit	$ 0			$ 0
2021 Notes [Member]
Debt Instrument, Convertible, Conversion Price		$ 17.11
Debt Instrument, Face Amount		$ 86,250,000
Debt Instrument, Interest Rate, Stated Percentage		5.50%
Proceeds from Debt, Net of Issuance Costs		$ 82,800,000
Repayments of Long-term Debt		18,600,000
Debt Instrument, Sinking Fund Payment		$ 0
Debt Conversion, Converted Instrument, Shares Issued		58.4454
Debt Conversion, Original Debt, Amount		$ 1,000
Debt Instrument Repurchase Price Equal to Percentage of Principal Amount		100.00%
Debt Instrument Conversion Term		1 year
Series D Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	15,499,324			15,499,324		1,079,453

Note E - Preferred Stock and Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended			12 Months Ended
	Jun. 02, 2014	May 31, 2015	Apr. 30, 2015	Feb. 28, 2015	Dec. 31, 2013	Jun. 30, 2016	Dec. 31, 2015
Common Stock [Member] \| IPO [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities			5,980,564
Common Stock [Member] \| Deerfield Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,923,077
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 5.85
Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					143,466	2,066,543
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 5.85
IPO [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities		5,980,564
Series D-1 Redeemable Convertible Preferred Stock [Member] \| Cowen KP Investment LLC [Member]
Temporary Equity Shares Issuance				3,200,000
Sale of Stock, Price Per Share				$ 1.25
Proceeds from Issuance of Redeemable Convertible Preferred Stock				$ 4.0
Conversion of Preferred Stock to Common Stock Upon Initial Public Offering Shares				415,584
Series D Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					1,079,453	15,499,324
Convertible Notes Payable [Member]
Debt Instrument, Face Amount					$ 3.8
2013 Warrants [Member]
Class of Warrant or Right Issued					1,079,453
Deerfield Warrant [Member]
Class of Warrant or Right Issued	14,423,076
Preferred Stock, Shares Outstanding						0	0
Preferred Stock, Shares Authorized		10,000,000	10,000,000			10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001			$ 0.0001	$ 0.0001

Note F - Common Stock and Warrants (Details Textual) - shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	May 31, 2015	Apr. 30, 2015	Dec. 31, 2012
Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						595,920
Common Stock, Shares, Outstanding	14,646,982		14,490,954
Common Stock, Shares Authorized	250,000,000		250,000,000	250,000,000	250,000,000
Common Stock, Shares, Issued	14,646,982		14,490,954
Common Stock Issued During Period from Warrants Exercised	141,095	12,251

Note F - Reserved Authorized Shares of Common Stock for Future Issuance (Details) - shares	Jun. 30, 2016	Dec. 31, 2015
Convertible Notes Payable [Member]
Common shares reserved for future issuance (in shares)	2,088,931	1,991,219
2021 Notes [Member]
Common shares reserved for future issuance (in shares)	5,040,914
Stock Compensation Plan [Member]
Common shares reserved for future issuance (in shares)	2,238,153	1,397,511
Possible Future Issuances Under Equity Incentive Plans [Member]
Common shares reserved for future issuance (in shares)	1,130,111	1,410,848
Warrant [Member]
Common shares reserved for future issuance (in shares)	2,087,477	2,325,383
Common shares reserved for future issuance (in shares)	12,585,586	7,124,961

Note F - Common Stock Activity (Details) - shares	3 Months Ended		6 Months Ended
Note F - Common Stock Activity (Details) - shares	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Balance (in shares)			14,490,954
Common stock warrants exercised (in shares)			141,095	12,251
Common stock options exercised (in shares)	14,933	0	14,933	0
Balance (in shares)	14,646,982		14,646,982

Note G - Stock-based Compensation (Details Textual) - USD ($)		3 Months Ended			6 Months Ended
	Jan. 02, 2016	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		2,846,304			2,846,304
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Reserved for Issuance, Incremental Percentage of Capital Stock Outstanding					4.00%
Increase in Common Stock Reserved for Issuance	579,638
Performance Shares [Member] \| Research and Development Expense [Member]
Allocated Share-based Compensation Expense					$ 29,000	$ 200,000
Performance Shares [Member] \| General and Administrative Expense [Member]
Allocated Share-based Compensation Expense			$ 600,000			700,000
Performance Shares [Member]
Allocated Share-based Compensation Expense		$ 0
Research and Development Expense [Member]
Allocated Share-based Compensation Expense		268,000	185,000		455,000	220,000
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense		$ 989,000	$ 688,000		$ 1,824,000	$ 744,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		14,933	0		14,933	0
Allocated Share-based Compensation Expense		$ 1,257,000	$ 873,000		$ 2,279,000	$ 964,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				134,665	13,333

Note G - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	$ 268	$ 185	$ 455	$ 220
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense	989	688	1,824	744
Allocated Share-based Compensation Expense	$ 1,257	$ 873	$ 2,279	$ 964

Note H - Fair Value of Financial Instruments (Details Textual) - USD ($)	3 Months Ended		5 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Oct. 31, 2013	Jun. 30, 2016	Jun. 30, 2015
Fair Value, Inputs, Level 3 [Member] \| Deerfield Facility Agreement [Member] \| Deerfield Convertible Notes [Member]
Long-term Debt, Fair Value	$ 8,500,000			$ 8,500,000
Fair Value, Inputs, Level 3 [Member] \| Deerfield Facility Agreement [Member] \| Term Notes [Member]
Long-term Debt, Fair Value	48,000,000			48,000,000
The 2013 Convertible Notes [Member] \| Unsecured Debt [Member]
Debt Instrument, Percentage Issued			10.00%
Changes Measurement [Member] \| Underwriter Warrant Liability [Member]
Fair Value Adjustment of Warrants				11,000
Changes Measurement [Member] \| Deerfield Warrant Liability [Member]
Fair Value Adjustment of Warrants				600,000
Changes Measurement [Member] \| Embedded Put Option [Member]
Fair Value Adjustment of Warrants				38,000
Changes Measurement [Member] \| Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member]
Fair Value Adjustment of Warrants				$ 7,000
Changes Measurement [Member]
Fair Value Assumptions, Expected Volatility Rate				10.00%
Fair Value Adjustment of Warrants	$ (20,763,000)	$ 22,661,000		$ (31,041,000)	$ 24,423,000

Note H - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Underwriter Warrant Liability [Member] \| Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Underwriter Warrant Liability [Member] \| Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Underwriter Warrant Liability [Member] \| Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	53	3,877
Underwriter Warrant Liability [Member]
Financial liabilities measured at fair value on recurring basis	53	3,877
Deerfield Warrant Liability [Member] \| Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Deerfield Warrant Liability [Member] \| Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Deerfield Warrant Liability [Member] \| Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	5,404	33,750
Deerfield Warrant Liability [Member]
Financial liabilities measured at fair value on recurring basis	5,404	33,750
Embedded Put Option [Member] \| Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Embedded Put Option [Member] \| Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Embedded Put Option [Member] \| Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	557	212
Embedded Put Option [Member]
Financial liabilities measured at fair value on recurring basis	557	212
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member] \| Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member] \| Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member] \| Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	29
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member]
Financial liabilities measured at fair value on recurring basis	29
Fair Value, Inputs, Level 1 [Member] \| Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis	11,911	8,951
Fair Value, Inputs, Level 1 [Member] \| Municipal Bonds [Member]
Financial assets measured at fair value on recurring basis	62,073	10,051
Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Financial assets measured at fair value on recurring basis	73,984	19,002
Fair Value, Inputs, Level 2 [Member] \| Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 2 [Member] \| Municipal Bonds [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 3 [Member] \| Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 3 [Member] \| Municipal Bonds [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	6,043	37,839
Financial assets measured at fair value on recurring basis
Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis	11,911	8,951
Municipal Bonds [Member]
Financial assets measured at fair value on recurring basis	62,073	10,051
Financial liabilities measured at fair value on recurring basis	6,043	37,839
Financial assets measured at fair value on recurring basis	$ 73,984	$ 19,002

Note H - Reconciliation of Beginning and Ending Balances for Derivative and Warrant Liability Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Balance at beginning of period	$ 27,479	$ 17,728	$ 37,839	$ 15,966
Reclassification of 2013 Convertible Notes		(1,110)		(1,110)
Exercise of warrants	(673)		(755)
Adjustment to fair value	(20,763)	22,661	(31,041)	24,423
Balance at end of period	$ 6,043	$ 39,279	$ 6,043	$ 39,279

Note I - Anti-dilutive Securities (Details) - shares	3 Months Ended	6 Months Ended
Note I - Anti-dilutive Securities (Details) - shares	Jun. 30, 2016	Jun. 30, 2016
Warrants to Purchase Common Stock [Member]
Antidilutive securities (in shares)	164,400	2,650,212
Stock Compensation Plan [Member]
Antidilutive securities (in shares)	2,238,153	943,304
Convertible Debt Securities [Member]
Antidilutive securities (in shares)	2,088,931	1,896,843
2021 Notes [Member]
Antidilutive securities (in shares)	5,040,914
Antidilutive securities (in shares)	9,532,398	5,490,359

Note I - Reconciliation of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Basic earnings per share of common stock:
Net earnings	$ 9,768	$ (29,743)	$ 6,834	$ (35,716)
Less: Net earnings allocable to participating securities	(1,137)		(798)
Net earnings allocable to shares of common stock	8,631		6,036
Less: Dividends declared or accumulated
Weighted-average shares of common stock outstanding (in shares)	14,597,449	12,157,514	14,546,576	7,272,326
Basic earnings per share of common stock (in dollars per share)	$ 0.59	$ (2.45)	$ 0.41	$ (4.91)
Diluted loss per share of common stock:
Net earnings	$ 9,768	$ (29,743)	$ 6,834	$ (35,716)
Less: Fair value adjustment for Deerfield stock warrants	(18,769)		(28,001)
Net loss allocable to shares of common stock, diluted	$ (9,001)		$ (21,167)
Weighted-average shares of common stock outstanding (in shares)	14,597,449	12,157,514	14,546,576	7,272,326
Dilutive effect of Deerfield stock warrants (in shares)	838,000		1,037,000
Weighted-average shares of common stock outstanding, diluted (in shares)	15,435,322	12,157,514	15,583,390	7,272,326
Diluted loss per share of common stock (in dollars per share)	$ (0.58)	$ (2.45)	$ (1.36)	$ (4.91)